UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
November
2, 2005 (October 31, 2005)
Date
of
Report (Date of earliest event reported)
COMPETITIVE
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
1-8696
|
36-2664428
|
(State
or other jurisdiction of
incorporation)
|
(Commission
File
Number )
|
(I.R.S.
Employer
|
1960
Bronson Road, Fairfield, Connecticut 06824
(Address
of principal executive offices) (Zip Code)
(203)
255-6044
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
□Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
□Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
□Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
□Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other
Events.
On
November 2, 2005, Competitive Technologies, Inc. (“CTT”) announced that the U.S.
Supreme Court has granted the writ of certiorari and agreed to hear the appeal
of Laboratory Corporation of America Holdings d/b/a LabCorp (“LabCorp”) in a
homocysteine patent case. The petition for appeal had been filed by LabCorp
in
its attempt to overcome an infringement ruling in a patent case in which
CTT's
patent rights, and those of its clients, had been upheld by both the U.S.
District Court and the Court of Appeals of the Federal Circuit. Recently,
the
U.S. Solicitor General, at the request of the U.S. Supreme Court, had
investigated a single issue of patentability presented in the petition for
appeal and recommended that the U.S. Supreme Court deny the writ of certiorari
and not hear the appeal. Nevertheless, the Court has decided to hear the
case on
the single issue of patentability.
A
copy of
the press release is attached as Exhibit 99.1.
Item
9.01. Financial
Statements and Exhibits
(c) Exhibits.
Exhibit
No. |
|
Description |
|
|
|
Exhibit 99.1 |
|
Press
release dated November 2, 2005.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
COMPETITIVE
TECHNOLOGIES, INC.
|
|
|
|
|
|
Date:
|
November
2, 2005
|
|
By:
|
/s/
Michael D. Davidson
|
|
|
|
Name:
|
Michael
D. Davidson
|
|
|
|
Title:
|
Vice
President and
|
|
|
|
|
Chief
Financial Officer
|
EXHIBIT
INDEX
Exhibit
No. |
|
Description |
|
|
|
Exhibit 99.1 |
|
Press
release dated November 2, 2005 announcing that the U.S. Supreme
Court has
granted the writ of certiorari and agreed to hear the appeal of
Laboratory
Corporation of America Holdings d/b/a LabCorp in a homocysteine
patent
case.
|